腎移植前後における処方薬剤の変化に関する調査

概要

論文の詳細を見る
Forty-two patients were surveyed regarding prescription changes and incidence of adverse events after undergoing renal transplantation at Gifu University Hospital. Immunosuppressive therapy including methylpredonisolone, tacrolimus, mycophenolate mofetil and basiliximab (monoclonal antibody against human interleukin-2 receptor) was administered after renal transplantation. As there was a significant increase in plasma concentrations of total cholesterol in 16 patients (171.0±19.4mg/dL to 234.7±20.8mg/dL) and a significant elevation of uric acid levels in 13 patients (5.3±1.3mg/dL to 8.7±0.5mg/dL) (P<0.01), drugs for hyperlipidemia and hyperuricemia were also prescribed for these patients. In addition to these changes, anti-osteoporosis agents were more frequently prescribed after transplantation. In contrast, there was a reduction in prescriptions for anti-hypertensive drugs and anti-hyperkalemia agents were reduced after the operation. The hyperlipidemia and hyperuremia were presumably adverse effects of the immunosuppressants and since they are known risk factors of graft rejection, we feel that it is important to check laboratory data and prescriptions for patients who have undergone renal transplantation in the practice of pharmaceutical care.
日本医療薬学会の論文
2007-11-10